Pharmaceuticals, Biotechnology and Life Sciences
Sustained enzyme activity up to 22 months and consistent trends demonstrated across multiple other measures in first patient in Fabry…
Excessive bleeding after birth, also known as postpartum haemorrhage (PPH), is the leading direct cause of maternal mortality worldwide,1 causing…
TOKYO–(BUSINESS WIRE)–Modulus Discovery, Inc., a preclinical-stage technology-driven drug discovery firm, announces the successful closing of its series B funding round…
Takeda has reported FY2019 revenue JPY 3,291 billion ($30.75M), up 57% in first full year following acquisition of Shire.
Earnings Call to be Conducted Wednesday, May 20 at 8:00 am ET HAWTHORNE, N.Y.–(BUSINESS WIRE)–Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced…
Gossamer Bio has reported a net loss for the first quarter 2020, was $54.1 million, or $0.87 per share, compared to a net loss of $32.6 million, or $0.90 per share, for the same period in 2019, while cash, cash equivalents and marketable securities totaled $346 million as of March 31, 2020.
Catabis expects top-line results in Q4 2020 from fully enrolled edasalonexent global phase 3 PolarisDMD trial in duchenne muscular dystrophy.
PhaseBio reported a net loss of $14.9 million for the three months ended March 31, 2020, which compared with a net loss of $7.3 million for the same period in 2019, which resulted in a net loss of $0.52.
Moderna has received FDA’s fast track designation for mRNA-1273 vaccine against the novel coronavirus, with finalizing protocol for Phase 3 study of mRNA-1273, expected to begin in early summer of 2020.
“When Sarclisa was added to standard-of-care treatment carfilzomib and dexamethasone in this phase 3 trial, results clearly demonstrated a significant reduction in risk of disease progression or death, ” said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi.